AltMountain

MPM Bioimpact

Boston, MA · CRD 148467
Hedge fund manager

MPM Bioimpact is an SEC-registered investment adviser based in Boston, MA that reports managing 3 hedge funds on Form ADV. It reports $3.6 billion in regulatory assets under management. Its private funds, of all types, hold $3.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +50.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +91.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$3.6 billionForm ADV Item 5.F
Gross assets of private funds
$3.5 billionAll private fund types, Form ADV
Hedge funds managed
314 private funds in total
Employees
50Form ADV Item 5.A
Registration
SEC-registered adviserCRD 148467
Latest Form ADV
04/28/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+50.1%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+91.0%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$1.6 billion37 positions, 2026-06-30
$72$132$191Q3 2024Q1 2025Q3 2025Q1 202613F est. $191S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+30.9%+14.8%
Q1 2026+14.7%-4.6%
Q4 2025+43.8%+2.4%
Q3 2025+19.9%+7.8%
Q2 2025+2.4%+10.4%
Q1 2025-17.0%-4.5%
Q4 2024-13.9%+2.1%
Q3 2024+0.9%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 36 share positions ($1,299,078,595) reported by MPM Bioimpact LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Cullinan Therapeutics Inc11.49%
  • Aktis Oncology Inc7.25%
  • Travere Therapeutics Inc4.93%
  • Edgewise Therapeutics Inc4.93%
  • Dyne Therapeutics Inc3.98%
  • Corcept Therapeutics Inc3.74%
  • Relay Therapeutics Inc3.29%
  • Trevi Therapeutics Inc3.28%
  • Iovance Biotherapeutics Inc3.23%
  • Liquidia Corporation3.13%
StockValue% of 13F portfolioSharesShares vs prior quarter
Cullinan Therapeutics Inc$149,218,59311.49%9,721,081-0.11%
Aktis Oncology Inc$94,154,4287.25%4,835,872Unchanged
Travere Therapeutics Inc$64,082,8134.93%1,088,363-3.06%
Edgewise Therapeutics Inc$63,985,0724.93%1,575,987-2.76%
Dyne Therapeutics Inc$51,683,2323.98%3,208,146+66.91%
Corcept Therapeutics Inc$48,627,0603.74%422,000-45.27%
Relay Therapeutics Inc$42,770,8833.29%2,369,578-1.91%
Trevi Therapeutics Inc$42,657,9343.28%2,978,906-3.08%
Iovance Biotherapeutics Inc$42,025,5783.23%2,835,734New
Liquidia Corporation$40,630,4953.13%1,342,713-3.14%
Natera Inc$37,439,6862.88%90,585-2.22%
Urogen Pharma LTD$36,960,7452.85%909,691-2.54%
Immunocore Hldgs PLC$36,447,6242.81%1,203,289New
DBV Technologies S A$35,805,1902.76%3,044,659-16.96%
Taysha Gene Therapies Inc$35,370,6102.72%7,262,959+61.40%
Abivax SA$32,516,0892.50%328,379-2.37%
Vir Biotechnology Inc$31,412,5692.42%2,809,711New
Adlai Nortye LTD$31,305,8882.41%1,956,618+1.05%
Verastem Inc$31,005,4122.39%3,851,604New
Uniqure NV$29,026,1382.23%1,201,413-1.99%
Odyssey Therapeutics Inc$28,643,6022.20%1,289,091New
Tarsus Pharmaceuticals Inc$27,723,8602.13%352,676+9.52%
Palvella Therapeutics Inc Ne$27,259,5202.10%197,633-3.13%
Aclaris Therapeutics Inc$27,236,9482.10%5,178,127+396.72%
Oruka Therapeutics Inc$24,987,0001.92%300,000New
Oric Pharmaceuticals Inc$24,541,6801.89%1,821,951-3.20%
Stoke Therapeutics Inc$24,053,4581.85%925,133+27.90%
Belite Bio Inc$22,651,7801.74%133,387-2.78%
Neurogene Inc$21,472,5611.65%771,839New
Zura Bio LTD$18,510,6311.42%4,449,671-0.52%
Annexon Inc$18,149,3061.40%4,290,616+21.05%
Monte Rosa Therapeutics Inc$13,423,8271.03%1,125,216-3.09%
Bioage Labs Inc$13,164,3431.01%1,856,748+11.34%
Corbus Pharmaceuticals Hldgs$11,370,7950.88%1,667,272New
Bright Minds Biosciences Inc$9,748,2300.75%195,669-3.19%
First Tracks Biotherapeutics$9,015,0150.69%254,374New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 9 new positions, 10 sold out, 8 increased, 18 reduced and 1 unchanged.

Number of positions (a count, not dollars)

  • New positions9
  • Increased8
  • Unchanged1
  • Reduced18
  • Sold out10

New positions

StockValueShares
Iovance Biotherapeutics Inc$42,025,5782,835,734
Immunocore Hldgs PLC$36,447,6241,203,289
Vir Biotechnology Inc$31,412,5692,809,711
Verastem Inc$31,005,4123,851,604
Odyssey Therapeutics Inc$28,643,6021,289,091
Oruka Therapeutics Inc$24,987,000300,000
Neurogene Inc$21,472,561771,839
Corbus Pharmaceuticals Hldgs$11,370,7951,667,272
First Tracks Biotherapeutics$9,015,015254,374

Sold out

StockValue at Jun 30, 2026Shares held then
Revolution Medicines Inc$92,232,216492,483
Alumis Inc$56,815,2232,019,020
Ultragenyx Pharmaceutical In$47,354,1991,418,215
Dianthus Therapeutics Inc$40,941,795420,002
Moonlake Immunotherapeutics$31,287,6471,606,967
Syndax Pharmaceuticals Inc$29,150,8131,333,523
Forte Biosciences Inc$20,983,270987,448
Entrada Therapeutics Inc$9,222,4701,253,053
Context Therapeutics Inc$719,5421,299,046
Werewolf Therapeutics Inc$28,85180,142

Largest increases

StockChange in sharesChangeValue nowShares now
Aclaris Therapeutics Inc+4,135,660+396.72%$27,236,9485,178,127
Dyne Therapeutics Inc+1,286,053+66.91%$51,683,2323,208,146
Taysha Gene Therapies Inc+2,762,959+61.40%$35,370,6107,262,959
Stoke Therapeutics Inc+201,819+27.90%$24,053,458925,133
Annexon Inc+746,262+21.05%$18,149,3064,290,616
Tarsus Pharmaceuticals Inc+30,669+9.52%$27,723,860352,676
Bioage Labs Inc+189,087+11.34%$13,164,3431,856,748
Adlai Nortye LTD+20,327+1.05%$31,305,8881,956,618

Largest reductions

StockChange in sharesChangeValue nowShares now
Corcept Therapeutics Inc-349,028-45.27%$48,627,060422,000
DBV Technologies S A-621,625-16.96%$35,805,1903,044,659
Travere Therapeutics Inc-34,368-3.06%$64,082,8131,088,363
Edgewise Therapeutics Inc-44,793-2.76%$63,985,0721,575,987
Trevi Therapeutics Inc-94,671-3.08%$42,657,9342,978,906
Liquidia Corporation-43,461-3.14%$40,630,4951,342,713
Urogen Pharma LTD-23,724-2.54%$36,960,745909,691
Palvella Therapeutics Inc Ne-6,394-3.13%$27,259,520197,633
Natera Inc-2,053-2.22%$37,439,68690,585
Relay Therapeutics Inc-46,094-1.91%$42,770,8832,369,578
Oric Pharmaceuticals Inc-60,211-3.20%$24,541,6801,821,951
Abivax SA-7,968-2.37%$32,516,089328,379
Belite Bio Inc-3,821-2.78%$22,651,780133,387
Uniqure NV-24,442-1.99%$29,026,1381,201,413
Monte Rosa Therapeutics Inc-35,865-3.09%$13,423,8271,125,216
Bright Minds Biosciences Inc-6,445-3.19%$9,748,230195,669
Cullinan Therapeutics Inc-10,260-0.11%$149,218,5939,721,081
Zura Bio LTD-23,172-0.52%$18,510,6314,449,671

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Forte Biosciences, Inc.13G amendment0%0Nov 13, 2026SEC.gov ↗
DBV Technologies S.A.13G amendment4.8%15,223,295Nov 13, 2026SEC.gov ↗
Corbus Pharmaceuticals Holdings, Inc.13G8.6%1,667,272Nov 13, 2026SEC.gov ↗
Context Therapeutics Inc.13G amendment1.4%1,299,046Aug 14, 2026SEC.gov ↗
Climb Bio, Inc.13G amendment0%0Aug 14, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Aug 14, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (21)

Fund
Gross assets
Minimum
Owners
Adviser
Oncology Impact Fund 2, L.P.
Cayman IslandsPrivate fund
Gross assets$826M
Minimum$5.0M
Owners32
AdviserMPM Bioimpact
UBS Oncology Impact Fund L.P.
Cayman IslandsPrivate fund
Gross assets$721M
Minimum$5.0M
Owners660
AdviserMPM Bioimpact
MPM Bioventures 2018, L.P.
Delaware, United StatesVenture capital fund
Gross assets$653M
Minimum$100K
Owners43
AdviserMPM Bioimpact
MPM Bioventures 2022, L.P.
Delaware, United StatesVenture capital fund
Gross assets$345M
Minimum$3.0M
Owners40
AdviserMPM Bioimpact
MPM Oncology Innovations Fund L.P.
Delaware, United StatesVenture capital fund
Gross assets$170M
Minimum$250K
Owners36
AdviserMPM Bioimpact
Bioimpact Equities Fund, LP
Delaware, United StatesHedge fund
Gross assets$154M
Minimum$1.0M
Owners40
AdviserMPM Bioimpact
MPM Bioventures 2014, L.P.
Delaware, United StatesVenture capital fund
Gross assets$148M
Minimum$100K
Owners61
AdviserMPM Bioimpact
Bioimpact Equities Master Fund, LP
Cayman IslandsHedge fund
Gross assets$99.0M
Minimum$1.0M
Owners11
AdviserMPM Bioimpact
MPM Bioventures IV-Qp, L.P.
Delaware, United StatesVenture capital fund
Gross assets$52.5M
Minimum$100K
Owners68
AdviserMPM Bioimpact
MPM Bioventures 2018 (B), L.P.
Delaware, United StatesVenture capital fund
Gross assets$33.9M
Minimum$200K
Owners8
AdviserMPM Bioimpact
MPM Bioventures V, L.P.
Delaware, United StatesVenture capital fund
Gross assets$20.4M
Minimum$100K
Owners29
AdviserMPM Bioimpact
MPM Asset Management Investors Bv2018 LLC
Delaware, United StatesVenture capital fund
Gross assets$13.6M
Minimum$38K
Owners24
AdviserMPM Bioimpact
MPM Bioventures 2014 (B), L.P.
Delaware, United StatesVenture capital fund
Gross assets$9.7M
Minimum$50K
Owners13
AdviserMPM Bioimpact
MPM Bio IV Nvs Strategic Fund, L.P.
BermudaVenture capital fund
Gross assets$7.3M
Minimum$100M
Owners2
AdviserMPM Bioimpact
MPM Bio 2014 Nvs Strategic Fund, L.P.
BermudaVenture capital fund
Gross assets$7.2M
Minimum$100K
Owners2
AdviserMPM Bioimpact
MPM Asset Management Investors Bv2014 LLC
Delaware, United StatesVenture capital fund
Gross assets$6.7M
Minimum$5K
Owners26
AdviserMPM Bioimpact
MPM Bio V Nvs Strategic Fund, L.P.
BermudaVenture capital fund
Gross assets$5.1M
Minimum$100K
Owners2
AdviserMPM Bioimpact
MPM Asset Management Investors Bv4 LLC
Delaware, United StatesVenture capital fund
Gross assets$3.3M
Minimum$10K
Owners28
AdviserMPM Bioimpact
MPM Asset Management Investors Bv5 LLC
Delaware, United StatesVenture capital fund
Gross assets$1.9M
Minimum$15K
Owners22
AdviserMPM Bioimpact
MPM Bioventures IV Gmbh & Co. Beteiligungs Kg
GermanyVenture capital fund
Gross assets$1.6M
Minimum$15.0M
Owners2
AdviserMPM Bioimpact
Oncology Investors of Texas Costim, LLC
Delaware, United StatesVenture capital fund
Gross assets$947K
Minimum$100K
Owners8
AdviserMPM Bioimpact

As reported in the adviser's Form ADV filed Jun 26, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​‌⁠